Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Anti-Cancer Drug Design|April 15, 2000
A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activityC Stratowa, A Baum, M J Castañon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumoursA Suder, J E Ang, F Kyle, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 20, 2019
CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrumC Morelli, C Tiloca, C Colombrita, et al.
Circulation Research|September 1, 1996
Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cellsL G Borges, R A Seifert, F J Grant, et al.
Oncogene|April 15, 2008
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsD Li, L Ambrogio, T Shimamura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Pageof 2